Literature DB >> 12695433

Diabetes: can we stop the time bomb?

M Fisher1.   

Abstract

Type 2 diabetes is increasing in prevalence and it is estimated that three million individuals in the UK will have the disease by 2010. People with diabetes have a high risk of cardiovascular disease-coronary heart disease is more prevalent, more extensive, and more diffuse. For all cardiovascular syndromes, the mortality is virtually doubled in patients with diabetes. Large clinical trials have provided clear evidence of the reduction in cardiovascular risk that can be achieved by treating hyperglycaemia as well as traditional risk factors, such as hypertension and hyperlipidaemia. The challenge now is for all health care professionals to implement the treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695433      PMCID: PMC1876292          DOI: 10.1136/heart.89.suppl_2.ii28

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  6 in total

1.  Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.

Authors:  Deepak L Bhatt; Steven P Marso; Alan T Hirsch; Peter A Ringleb; Werner Hacke; Eric J Topol
Journal:  Am J Cardiol       Date:  2002-09-15       Impact factor: 2.778

2.  The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

Authors:  A F Amos; D J McCarty; P Zimmet
Journal:  Diabet Med       Date:  1997       Impact factor: 4.359

3.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

4.  Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study.

Authors:  Nick A Roper; Rudy W Bilous; William F Kelly; Nigel C Unwin; Vincent M Connolly
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.

Authors:  Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

  6 in total
  2 in total

1.  Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes.

Authors:  S J Hong; M H Kim; T H Ahn; Y K Ahn; J H Bae; W J Shim; Y M Ro; D-S Lim
Journal:  Heart       Date:  2006-01-31       Impact factor: 5.994

Review 2.  Diabetes: preventing coronary heart disease in a high risk group.

Authors:  M D Feher
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.